Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The Food and Drug Administration's decision on Monday to lift the partial hold on Gilead Sciences Inc.'s GILD, -0.66% magrolimab for two indications is "good news" for the company, according to RBC Capital Markets analysts. "While GILD still has much to prove around its emerging oncology franchise, we see this as a much-needed piece of good news," analysts wrote in a note to investors on Monday.

RBC: the FDA lifting the hold on Gilead's experimental cancer therapy is a 'much-need piece of good news'

The U.S. Food and Drug Administration has lifted a partial clinical hold on studies evaluating magrolimab in combination with azacitidine, Gilead Sciences Inc. said Monday.

Dow Jones Newswires: Gilead says FDA lifts partial clinical hold on MDS and AML magrolimab studies

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) lifted the partial clinical hold placed on studies evaluating its investigational agent magrolimab in combination with azacitidine. The FDA removed the partial clinical hold after a review of the comprehensive safety data from each trial. With today's decision from the FDA, enrollment in the U.S. can resume for the studies investigating magrolimab in combin

FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies

Bristol-Myers

PRINCETON, N.J.--(BUSINESS WIRE)--BMS Foundation Honors Diversity & Health Equity Leader By Naming Diversity in Clinical Trials Training Program After Him; Welcomes Gilead Sciences

Bristol Myers Squibb Foundation Honors Diversity and Health Equity Leader By Naming Diversity in Clinical Trials Training Program After Him; Welcomes Gilead Sciences as Program Supporter

Archer-Daniels-Midland Company

Aflac

Allegion

Amgen

Broadcom

Becton, Dickinson and Co.

Dover

Con Ed

Emerson Electric

W.W. Grainger

Johnson & Johnson

Kraft Heinz

Kontoor Brands Inc

LyondellBasell Industries

McDonald's

Microsoft

PepsiCo

Pfizer

Southern Company

T. Rowe Price Group

Trane Technologies plc

Unilever

The start of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated.

Dividend Income Update March 2022

Gilead's HIV pipeline is the heart of the company's revenue stream, the other viral regimens not as much.

Gilead Sciences: A Hindered Pipeline With Abundant Potential

Gilead is a leader in anti-viral therapies.

Gilead: Buy For Dividend, HIV And Cancer Therapies

Best Buy

Conagra Brands

Foot Locker

Kimberly-Clark

Texas Instruments

After the first down quarter since 2020, many across Wall Street are examining the winners and losers for the quarter and shuffling the deck, looking for stocks that have the best upside potential for the second quarter and beyond.

Top Analysts Say 8 Q1 Underperforming Dividend Stocks Could Be Huge Q2 Winners

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved Yescarta® (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Yescarta demonstrated a clinically meaningful and statistically significant improvement in event-free survival (EFS; hazard rat

Yescarta® Receives U.S. FDA Approval as First CAR T-cell Therapy for Initial Treatment of Relapsed or Refractory Large B-cell Lymphoma (LBCL)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc., (Nasdaq: GILD) today announced $24 million in grants to help reduce health disparities, improve access to quality healthcare, advance medical education and support local communities most impacted by the HIV epidemic and COVID-19 pandemic. The Zeroing In: Ending the HIV Epidemic program, will support 116 organizations in 41 countries. The funding recipients will focus on advancing at least one of three focus areas: Comprehensive HIV In

Gilead Sciences Announces $24 Million in Grants to Help End the HIV Epidemic for Everyone, Everywhere

Gilead Sciences and Unilever both currently yield over 4%.

2 High-Yielding Stocks Trading Near Multiyear Lows

Cogent Communications Holdings

Main Street Capital

ONEOK

Philip Morris

We're looking at a screening of dividend stocks that could be worthwhile for further exploration

March's 5 Dividend Growth Stocks With 4.64%+ Yields

AbbVie

Eli Lilly

Merck

Walgreens

To say that hedge fund and mutual fund managers tend to follow the herd is an incredible understatement and always has been.

Fund Managers Pile Into Big Dividend Health Care Stocks: 8 ‘Strong Buy' Winners

Intel

Stocks have been pounded all year long, and many of those taking the biggest hit are in the Nasdaq composite index, which as of Friday's close was officially in bear market territory.

5 ‘Strong Buy' Nasdaq Stocks That Also Pay the Biggest Dividends in the Index

Gilead (GILD) has struggled for a number of years and the 5-year annualized total return is 0.6% per year.

Outlook On Gilead Is A Mixed Bag

Gilead Sciences, Inc. (GILD) Presents at Cowen Annual Health Care Conference (Transcript)

Gilead Sciences, Inc. (GILD) Management Presents at Raymond James 43rd Annual Institutional Investors Conference (Transcript)

While Gilead's (GILD) phase III study evaluating Trodelvy in late-line HR+/HER- breast cancer did achieve its primary endpoint, the lack of numerical data puts ambiguity on the significance of results.

Gilead's (GILD) Trodelvy Late-Line Breast Cancer Study Meets Goal

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from the Phase 3 TROPiCS-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic breast cancer who received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy. The study met its primary endpoint with a statistically significant improvement in progression-free survival (PFS) versus physician's choice of chemotherapy. The trial t

Phase 3 TROPiCS-02 Study Met the Primary Endpoint of Progression-Free Survival in Late-Line HR+/HER2- Metastatic Breast Cancer

Devon Energy

Huntington Bancshares

Simon Property Group

Verizon

We have always championed dividend stocks at 24/7 Wall St., especially those with higher payouts and growth rates.

Goldman Sachs Says Buy High-Dividend Stocks That Help Counter Inflation: 6 Top Picks

Gilead (GILD) reported earnings 30 days ago. What's next for the stock?

Gilead (GILD) Down 7% Since Last Earnings Report: Can It Rebound?

Gilead Sciences ( GILD , Financial) had a particularly strong 2021 with the full-year revenue being 11% higher than the midpoint of their initial guidance released in February 2021. The impact of Covid-19 on HIV and HCV revenues in 2021 was more than offset by increased Veklury sales, and this drug continues to play a critical role in helping to treat people with Covid-19, including the Omicron variant.

Gilead Sciences: A Year Without the Veklury Upside

Shares of Gilead Sciences Inc. GILD, -1.18% were down 1.0% in premarket trading on Tuesday after the company said it received a complete response letter from the Food and Drug Administration regarding its application for an experimental HIV drug. Gilead is seeking FDA approval for lenacapavir, a long-acting HIV-1 capsid inhibitor, for people with multi-drug resistant HIV.

Gilead gets a complete response letter from FDA about the vial used to store an experimental HIV drug

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the New Drug Application (NDA) for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor under review for the treatment of HIV-1 infection in heavily treatment-experienced (HTE) people with multi-drug resistant (MDR) HIV-1 infection. In the CRL, the FDA has cited Chemistry Manufacturing and Controls (

Gilead Receives Complete Response Letter From U.S. FDA for Investigational Lenacapavir Due to Vial Compatability Issues

Deciphera Pharmaceuticals

The S&P 500, Nasdaq and Dow Jones industrial average have all entered correction territory within the past month, and investors took the brunt of this.

News for Gilead Sciences Stock (GILD)